Literature DB >> 22402813

Management of the neck in the setting of definitive chemoradiation: is there a consensus? A GETTEC study.

Juliette Thariat1, Marc Hamoir, Renaud Garrel, Alain Cosmidis, Olivier Dassonville, C A Righini, P O Vedrine, J M Prades, J Lacau-Saint-Guily, F Jegoux, O Malard, E De Mones, A Benlyazid, R-J Bensadoun, B Baujat, J C Merol, C Ferron, C Scavennec, D Salvan, Y Mallet, S Moriniere, S Vergez, O Choussy, G Dollivet, N Guevara, P Ceruse, D De Raucourt, B Lallemant, G Lawson, P Lindas, M Poupart, S Duflo, Xavier Dufour.   

Abstract

BACKGROUND: The management of the neck remains controversial in the definitive chemoradiation setting of advanced N2-3 head and neck squamous cell carcinoma. Most published data favor omission of neck dissection (ND) after complete response for N2-3 or selective ND for residual disease
METHODS: We studied the patterns of care in the French-Belgian Groupe d'Etude des Tumeurs de la Tête Et du Cou (GETTEC) through a questionnaire-based survey.
RESULTS: Eighteen percent of institutions never performed up-front ND, 20% rarely, 40% sometimes, 14% often, and 8% systematically. Induction chemotherapy was indicated in 30% of the cases, and most ND were performed either between induction and radiation or after chemoradiation for residual disease. Response to chemoradiation was assessed by computed tomographic scan and positron emission tomography in 72% of cases. Selective ND was more common than radical ND.
CONCLUSIONS: Omission of ND based on computed tomographic scan and positron emission tomography-based complete response to chemoradiation is the most common strategy for advanced nodal disease among centers. However, neck management strategies vary among institutions, and some institutions continue advocating systematic ND before irradiation. The new treatment options and the changing epidemiology, namely docetaxel-based induction chemotherapy and human papilloma virus-related head and neck squamous cell carcinoma having better response profiles and prognosis, are adding to the nonconsensual approach. The best therapeutic index in terms of neck management remains to be defined in this evolving context.

Entities:  

Mesh:

Year:  2012        PMID: 22402813     DOI: 10.1245/s10434-012-2275-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

Review 1.  The evolving role of selective neck dissection for head and neck squamous cell carcinoma.

Authors:  K Thomas Robbins; Alfio Ferlito; Jatin P Shah; Marc Hamoir; Robert P Takes; Primož Strojan; Avi Khafif; Carl E Silver; Alessandra Rinaldo; Jesus E Medina
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-19       Impact factor: 2.503

2.  Up-front neck dissection followed by chemoradiotherapy for T1-T3 hypopharyngeal cancer with advanced nodal involvement.

Authors:  Mitsuo P Sato; Naoki Otsuki; Mutsukazu Kitano; Kazuki Ishikawa; Kaoru Tanaka; Takayuki Kimura; Katsumi Doi
Journal:  Head Neck       Date:  2021-09-22       Impact factor: 3.821

3.  A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery).

Authors:  Pavel Dulguerov; Martina A Broglie; Guido Henke; Marco Siano; Paul Martin Putora; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Olgun Elicin
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.